Ventricular Premature Complexes Diagnosis and Treatment

Introduction

Ventricular premature complexes (VPCs) are a common cardiac arrhythmia that can be benign or associated with underlying heart disease, with a risk level determined by the burden, as stated by the American College of Cardiology and the European Society of Cardiology 1, 2

The European Society of Cardiology recommends localization of VPCs using a combination of 12-lead ECG morphology analysis, activation mapping, and pacemapping during electrophysiology studies, with treatment decisions based on symptom severity, VPC burden, and presence of structural heart disease 2
Typical ECG characteristics of VPCs include LBBB morphology, inferior axis, later R/S transition, and shorter cycle lengths compared to LVOT VPCs, and are more frequently associated with syncope 2
The American College of Cardiology suggests using 24-hour Holter monitoring to quantify VPC burden and assess for complex ventricular arrhythmias, and echocardiogram to assess ventricular function and rule out structural heart disease 3
Contrast-enhanced cardiac MRI is recommended for patients with ≥2,000 VPCs per 24h, episodes of non-sustained ventricular tachycardia, or increasing ectopy during exercise testing 3
Diagnostic workup for trigeminy may involve a 12-lead ECG, 24-hour Holter monitoring, echocardiography, and exercise stress testing, as suggested by the American College of Cardiology, to quantify PVC burden and assess ventricular function 4
The risk level of VEBs can be determined by the burden, with the following categories:

PVC Burden	Risk Level	Clinical Significance
<2,000/24h or <1%	Very Low	Generally benign
2,000-10%	Low to Intermediate	May require monitoring
10-15%	High	Minimum threshold that can result in cardiomyopathy
>15%	Very High	Strong association with adverse outcomes
≥24%	Extremely High	Independently associated with cardiomyopathy

5, 6, 7

Beta-blockers, such as propranolol, are recommended as first-line therapy for VPCs, with non-dihydropyridine calcium channel blockers and class I or III antiarrhythmic medications as alternative options 7, 8, 9, 2, 10, 1
Class IC antiarrhythmic drugs are recommended as second-line therapy, especially for LVOT/aortic cusp/epicardial VPCs 2
Ablation is recommended for symptomatic RVOT VPCs after failure of beta-blocker therapy or in patients with LV dysfunction due to high VPC burden, with success rates >95% and low complication rates 2
Ablation of LVOT/Aortic Cusp/Epicardial VPCs should be considered after failure of at least one sodium channel blocker, requiring careful mapping and understanding of complex anatomy 2
The following treatment recommendations are based on PVC burden:

PVC Burden	Risk Level	Recommendation
<10%	Low	Medical therapy if symptomatic
10-15%	Intermediate	Consider medical therapy first
>15%	High	Consider catheter ablation
>24%	Very High	Strong indication for catheter ablation

7, 8, 9, 2, 10, 1

Catheter ablation carries higher complication rates in young children and should only be considered as second-line therapy in experienced centers, according to the European Society of Cardiology and the Pediatric and Congenital Electrophysiology Society 9, 2
Lidocaine is indicated for ventricular premature beats that are frequent, closely coupled, multiform in configuration, or occur in short bursts of three or more in succession, as recommended by the American College of Cardiology 11

Patients with VPCs should limit caffeine, alcohol, and stimulants, manage stress and anxiety, and consider limiting high-intensity physical activities if PVC burden is high, as recommended by the American Heart Association, the European Society of Cardiology, and the American College of Cardiology 9, 2, 10, 12
Annual cardiac evaluation is recommended to monitor for development of cardiomyopathy in patients with high PVC burden, according to the American Heart Association, the American College of Cardiology, and the European Society of Cardiology 10, 2
Patients with PVC burden >10% without symptoms or structural heart disease may require monitoring for development of cardiomyopathy and follow-up echocardiography to assess ventricular function, as recommended by the Heart Rhythm Society 2
24-hour Holter monitoring is essential to quantify PVC burden accurately, as recommended by the American College of Cardiology and the European Society of Cardiology 9, 2, 10
Follow-up Holter monitoring is recommended after initiating therapy to assess treatment response 7

Asymptomatic children with frequent isolated PVCs and normal ventricular function should be followed without treatment, and verapamil should be avoided in infants <1 year due to risk of hemodynamic deterioration, as suggested by the American Academy of Pediatrics, the European Society of Cardiology, and the Pediatric and Congenital Electrophysiology Society 9, 2
In patients with thalassemia, frequent PVCs may indicate iron cardiotoxicity, especially when occurring as couplets or with nonsustained ventricular tachycardia, as noted by the American Heart Association 13
Patients with an ischemic or nonischemic cardiomyopathy, particularly those with ejection fraction <35%, history of heart failure, and nonsustained ventricular tachycardia may benefit from ICD therapy, as suggested by the American College of Cardiology 14
Patients with structural heart disease may require more aggressive evaluation and treatment, including consideration of ICD therapy for those with sustained ventricular arrhythmias and cardiomyopathy, as recommended by the European Heart Rhythm Association 2